Anuh Pharma Limited Overview
Anuh Pharma is a small-cap, single-site, debt-free Indian manufacturer of active pharmaceutical ingredients (APIs). Its business rests on off-patent, mature anti-infective molecules. It claims to be India's largest producer of erythromycin salts, among the top five globally, and the world's largest producer of pyrazinamide (ICRA, Sep 2025). Its Tarapur (Boisar) plant has 2,400 MTPA of capacity across nine API blocks and two intermediate blocks. The plant holds approvals from USFDA (a no-observation inspection in early 2026), EU GMP (Spanish AEMPS), WHO pre-qualification, and multiple EDQM CEPs. Anuh sells to about 360 customers and marketing partners in more than 72 countries. Exports were about 46% of FY26 revenue, mainly to Asia, Africa and Europe. FY26 revenue from operations was INR 771.7 Cr (+16.7%). Margins, however, compressed to an EBITDA margin of 8.6% because of price competition in commoditised molecules. Management's strategy is to move volume toward regulated markets and newer molecules (anti-diabetics, anti-coagulants, new anti-TB and anti-malarials) while keeping the balance sheet ungeared. It guides to 15–20% annual growth.
What the company does
Anuh Pharma makes and sells bulk drugs (APIs) and some intermediates. Pharmaceutical formulators in India and abroad buy these and turn them into finished dosage forms.
Under Ind AS 108, the company reports a single operating segment, "Bulk drugs and Chemicals". It therefore publishes no segment financials (FY25 audited results, note 6; Q3 FY26 results, note 7).
The portfolio covers 12 therapeutic categories:
-
macrolides (erythromycin salts)
-
higher macrolides (azithromycin)
-
corticosteroids (15 molecules)
-
anti-TB (pyrazinamide, isoniazid)
-
anti-malarials (sulfadoxine, pyrimethamine, amodiaquine)
-
anti-diabetics (gliclazide, vildagliptin, dapagliflozin)
-
anti-bacterials (chloramphenicol and its palmitate)
-
expectorants (ambroxol HCl, acefylline piperazine)
-
an anti-asthmatic (acebrophylline)
-
an antihistamine (bilastine, listed as "Bilsatin")
-
a quinolone (moxifloxacin)
-
an antibiotic (sulfadimethoxine)
-
an anti-gout drug (allopurinol)
Source: Q1 FY27 investor presentation, Aug 2026.
Company's own description
In its investor materials, the company describes itself as one of India's largest makers of macrolides and anti-TB products. It also calls itself a significant player in anti-bacterials, anti-malarials, anti-hypertensives and corticosteroids, with marketing partnerships across about 360 customers in more than 72 countries, including Europe, Mexico and South Africa.
It lists leading positions in:
-
erythromycin salts
-
pyrazinamide
-
sulfadoxine
-
ambroxol HCl
-
gliclazide
-
clobetasol propionate
-
betamethasone dipropionate
The reasons it gives for customer preference are:
-
regulatory approvals
-
EHS compliance audited by multinationals
-
diversified sourcing with backward integration in key products
-
spare capacity
-
a debt-free balance sheet with steady dividends
-
a DSIR-approved R&D centre
Source: Q1 FY27 investor presentation; FY25 annual report summary as reproduced by Screener.
Business model and revenue model
| Dimension | Characterisation |
|---|---|
| Revenue model mix | About 100% product sales (API manufacturing plus some traded goods). No subscription, licensing or service revenue is disclosed. Purchases of stock-in-trade were INR 79.2 Cr in FY26 (about 10% of revenue from operations), against INR 38.5 Cr in FY25. Trading is therefore a material and growing secondary activity. |
| Pricing | Spot and contract pricing for generic APIs, plus institutional tenders. The WHO-prequalified anti-malarials and anti-TB molecules feed donor-funded procurement chains. |
| Value-chain position | Mid-stream. Anuh buys key starting materials and intermediates (for example erythromycin thiocyanate, mostly from fermentation-based producers, and steroid intermediates), converts them into salts and APIs, and sells to formulators. ICRA credits selective backward integration in key products. |
| Customer types | Domestic and international generic formulators, multinational pharma companies (which audit the site), marketing and trading partners, and institutional and tender-linked buyers for WHO-PQ molecules. |
| Concentration | Top-five customers took 42% of FY26 export sales (FY26 investor presentation). Top-five customers' share of total sales fell to 20% in Q1 FY27 from 36% in Q1 FY26 (Q1 FY27 presentation). |
| End-markets | Domestic India (about 54% of FY26 revenue). Export (about 46%) to Asia 35%, Africa 33%, Europe 24%, North America 5% and Latin America 3% (FY26 investor presentation). |
Sources: FY26 audited results (20 May 2026); Q1 FY27 results (7 Aug 2026); FY26 and Q1 FY27 investor presentations.
Independent characterisation
Anuh is a commodity-API converter. Its competitive edge comes from three things: regulatory credentials (EU GMP, CEPs, WHO-PQ and now a clean USFDA inspection), process cost, and customer relationships. It does not rely on intellectual property.
Most of its revenue comes from mature, multi-sourced molecules. ICRA's September 2025 rationale says this exposes margins to price competition and raw-material swings. Erythromycin alone was about 31% of FY26 product revenue (INR 241 Cr of INR 772 Cr).
The business is lightly capitalised. Net fixed assets were about INR 56 Cr against INR 772 Cr of revenue in FY26. Working-capital intensity is high and rising: the cash conversion cycle went from 58 days in FY22 to 86 days in FY26.
The balance sheet is very conservative. Total debt was effectively nil at FY26 year-end, and the company held about INR 53 Cr of cash and liquid investments plus INR 40 Cr of long-term investments.
Management's strategic intent is to shift the mix toward regulated markets and toward molecules with less commoditised pricing. Q1 FY27 margin expansion is the first evidence that this is working.
Strategy
Stated strategy
These themes are paraphrased from the FY26 and Q1 FY27 investor presentations ("Future Outlook — Growth Strategy"):
-
Volume expansion with regulated-market growth. Grow volumes across API lines while shifting toward higher-value regulated markets. The USFDA and EU GMP clearances are described as making the regulated-market pipeline the primary growth engine.
-
Process innovation and cost optimisation, as a continuing priority for competitiveness in commoditised molecules.
-
Market diversification focused on exports, explicitly framed as reducing currency risk.
-
Continued investment in compliance, operational efficiency and capacity, funded internally.
-
Portfolio diversification and operating leverage, from new molecules and better throughput of existing assets.
The Joint MDs' Q1 FY27 letter credits three levers for margin improvement: a richer product mix, disciplined cost control, and higher throughput from existing assets.
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Capacity expansion to 2,200 MTPA | FY25 (around Mar 2025) | Funded by internal accruals; FY25 capex about INR 20 Cr | Completed |
| Capacity expansion to 2,400 MTPA | Effective 15 Jul 2025 | 40 KL of added reactor capacity | Completed |
| USFDA re-inspection | Disclosed 6 Feb 2026 | Zero Form 483 observations | Completed |
| WHO-PQ for amodiaquine HCl | 2,026 | Opens SPAQ (seasonal malaria chemoprevention) institutional demand | Completed |
| EDQM CEP for sulfadimethoxine | 2,025 | EU market access | Completed |
| EcoVadis Bronze medal | 2,026 | Supply-chain sustainability rating demanded by MNC customers | Achieved |
| Pipeline: vonoprazan, pretomanid, edoxaban, bisoprolol (plus ticagrelor, linagliptin, pyronaridine, ethambutol per ICRA) | 2025–26 | Diversification away from mature macrolides and steroids | Under development; no timelines disclosed |
| Marketing initiatives in regulated and unregulated markets; new CMO for regulated markets | FY26 | Per ICRA and senior-management roster | Ongoing |
| Bonus issue 1:1 | Jul 2025 | Improves liquidity of a thinly traded stock | Completed |
| Revised governance policies (RPT, dividend distribution, materiality, NRC, fair-disclosure code) | May 2025; revised RPT policy Aug 2026 | Regulatory alignment | Completed |
| Japan approval ("Pharma Copia, Japan") | Referenced in ICRA Jan 2025 | Approval sought from a Japanese counterparty | Unconfirmed status |
No quantified emissions targets are disclosed.
Cost programmes with targets. None quantified publicly.
Medium-term guidance
| Guidance item | Statement | Source |
|---|---|---|
| Revenue growth | "Steady" 15–20% per annum growth anticipated | FY26 deck (May 2026); Q1 FY27 deck (Aug 2026) |
| Margin targets | Not quantified | — |
| Capex | No debt-funded capex planned in the near term | ICRA Sep 2025 |
| Dividend | Consistent dividend record. A revised dividend distribution policy was adopted (May 2025); quantum not specified. | Board outcome, May 2025 |
Implied check. 15–20% growth on FY26 revenue of INR 772 Cr implies FY27 revenue of INR 887–926 Cr. Q1 FY27 revenue of INR 193.8 Cr (+3.9%) means the remaining three quarters need about 20–25% YoY growth to hit the low end (derived).
Products & Services
All products sit within the single "Bulk drugs & chemicals" segment and are grouped below by therapeutic category, as in the company's portfolio slide.
Pricing. No list prices are disclosed for any product. APIs sell business-to-business at negotiated prices. Launch years for individual molecules are not disclosed except where the regulatory milestone date is a proxy.
Macrolides (erythromycin family) — flagship franchise
| Product | Description / use | Key credentials | Target customer | Milestone year |
|---|---|---|---|---|
| Erythromycin base | Macrolide antibiotic API | EU GMP / CEP (2010) | Generic formulators, EU and RoW | 1989 franchise start; CEP 2010 |
| Erythromycin estolate | Oral salt (suspensions) | COFEPRIS Mexico (2014) | LatAm and RoW formulators | 2,014 |
| Erythromycin stearate | Oral tablet salt | COFEPRIS (2014); UK MHRA DMF (2017) | UK, EU, LatAm | 2,017 |
| Erythromycin ethyl succinate | Paediatric oral salt | CEP/EU GMP (2010); COFEPRIS (2014) | Global formulators | 2,010 |
| Erythromycin propionate | Salt form | — | RoW | — |
| Erythromycin phosphate | Salt form | — | RoW | — |
| Erythromycin 11,12-carbonate | Derivative / intermediate | — | Formulators / derivative makers | — |
The company claims to be India's largest erythromycin-salt producer and among the global top five (ICRA, Sep 2025). Erythromycin revenue was INR 241 Cr in FY26, about 31% of revenue.
Higher macrolides
| Product | Description | Credentials | FY26 revenue |
|---|---|---|---|
| Azithromycin | Broad-spectrum macrolide | EDQM CEP (2023) | INR 110 Cr (group), +62% YoY |
| Roxithromycin | Macrolide (cited by ICRA as a portfolio product) | — | Included in group |
Corticosteroids (15 molecules)
The portfolio comprises:
-
Beclomethasone dipropionate
-
Betamethasone acetate
-
Betamethasone dipropionate
-
Betamethasone sodium phosphate
-
Betamethasone valerate
-
Clobetasol propionate
-
Deflazacort
-
Dexamethasone sodium phosphate
-
Dexamethasone acetate
-
Mometasone furoate
-
Prednisolone acetate
-
Prednisolone sodium phosphate
-
Triamcinolone acetonide
-
Triamcinolone base
-
Methyl prednisolone
The flagship molecules, where the company claims leadership, are clobetasol propionate and betamethasone dipropionate. Group revenue was INR 82 Cr in FY26, down 20% YoY. The targets are topical, ophthalmic, injectable and oral steroid formulators. A secondary source also lists clobetasol butyrate, but this is not in the company's current portfolio slide.
Source: Q1 FY27 presentation; FY26 presentation summary.
Anti-tuberculosis
| Product | Credentials | Notes |
|---|---|---|
| Pyrazinamide | CEP/EU GMP (2010); WHO-PQ (2012 per IIFL; 2019 per company timeline); EU GMP AEMPS (2019) | Company claims world's largest producer (ICRA). FY26 revenue INR 42 Cr. |
| Isoniazid | WHO-PQ (2024) | Newer addition |
| Pretomanid | Pipeline (under development) | Next-generation anti-TB, used in BPaL-type regimens |
| Ethambutol | Pipeline (ICRA list, Sep 2025) | Completes a first-line TB "basket" |
Anti-malarials
| Product | Credentials | Notes |
|---|---|---|
| Sulfadoxine | WHO-PQ (2015, renewed 2019); EDQM CEP (2023) | FY26 revenue INR 100 Cr (+11%). Q1 FY27 INR 37 Cr vs INR 11 Cr. |
| Pyrimethamine | WHO Geneva PQ (2019/2020) | Partner molecule to sulfadoxine (SP combination) |
| Amodiaquine HCl | WHO-PQ (2026) | Enables SPAQ seasonal malaria chemoprevention supply |
| Pyronaridine tetraphosphate | Pipeline (ICRA list) | Artemisinin-combination partner drug |
Anti-diabetics
| Product | Credentials | Notes |
|---|---|---|
| Gliclazide | EDQM CEP (2023) | FY26 revenue INR 21 Cr (-25%). Q1 FY27 INR 11.9 Cr vs INR 5.1 Cr. |
| Vildagliptin | — | DPP-4 inhibitor; off-patent in many markets |
| Dapagliflozin | — | SGLT2 inhibitor; generic opportunity as exclusivities lapse |
| Linagliptin | Pipeline (ICRA list) | DPP-4 inhibitor |
Anti-bacterials, antibiotics and quinolones
| Product | Credentials | Notes |
|---|---|---|
| Chloramphenicol | COFEPRIS (2015) | Q1 FY27 INR 4.0 Cr vs INR 12.2 Cr |
| Chloramphenicol palmitate | COFEPRIS (2015) | Paediatric oral |
| Sulfadimethoxine (and sodium salt) | EDQM CEP (2025) | Sulfonamide; used heavily in veterinary medicine |
| Moxifloxacin | — | Fourth-generation fluoroquinolone |
Respiratory, anti-allergy, anti-gout, others
| Product | Category | Credentials |
|---|---|---|
| Ambroxol HCl | Expectorant / mucolytic | EDQM CEP (2024); claimed leadership. Q1 FY27 INR 7.9 Cr. |
| Acefylline piperazine | Bronchodilator / expectorant | — |
| Acebrophylline | Anti-asthmatic | — |
| Bilastine (listed as "Bilsatin") | Antihistamine | — |
| Allopurinol | Anti-gout | EDQM CEP (2024) |
Development pipeline
| Molecule | Therapy area | Source | Status |
|---|---|---|---|
| Vonoprazan fumarate | Anti-ulcer (potassium-competitive acid blocker) | Q1 FY27 and FY26 presentations; ICRA | Under development |
| Pretomanid | Anti-TB | Q1 FY27 presentation | Under development |
| Edoxaban tosylate | Anti-coagulant (factor Xa inhibitor) | Q1 FY27 presentation | Under development |
| Bisoprolol fumarate | Beta-blocker / anti-hypertensive | Q1 FY27 presentation | Under development (added Aug 2026) |
| Ticagrelor | Anti-platelet | ICRA Sep 2025 | Development stage |
| Linagliptin | Anti-diabetic | ICRA Sep 2025 | Development stage |
| Pyronaridine tetraphosphate | Anti-malarial | ICRA Sep 2025 | Development stage |
| Ethambutol | Anti-TB | ICRA Sep 2025 | Development stage |
| Sulfadimethoxine sodium | Antibiotic | ICRA Sep 2025 | CEP received 2025 |
Services: none. The company does not disclose any contract development and manufacturing (CDMO) or custom-synthesis business.
Financial Narrative
Data notes
-
Revenue from operations and PAT for FY24–FY26 come from audited exchange filings.
-
FY22–FY23 lines and the gross-profit, EBIT and cash-flow lines come from S&P Global Market Intelligence via StockAnalysis.com (in INR mn), converted to INR Cr.
EBITDA is shown on two bases: - (a) the company's definition, which includes other income and is reported in results notes and the investor deck;
-
(b) S&P's definition, which is EBIT plus D&A and excludes non-operating items.
-
The FY26 investor deck's five-year chart shows FY26 PAT as 47.4. That conflicts with the audited FY26 PAT of INR 41.05 Cr and appears to be a typographical repetition of FY25. The audited figure is used here.
-
Total revenue (including other income) was INR 776.0 Cr in FY26. This explains the 15.66% growth rate cited in management commentary, against 16.65% on revenue from operations.
Income statement
Sources: FY24–FY26 audited results (BSE/NSE); FY22–FY26 investor deck five-year track record; StockAnalysis/S&P income statement (updated 7 Aug 2026).
Per-share data (INR, adjusted for the 1:1 bonus of July 2025):
Notes:
-
FY25 EPS was reported as INR 9.45 pre-bonus (FY25 audited results); the Q3 FY26 filing restates it to INR 4.72.
-
The FY24 dividend was INR 2.50 on pre-bonus shares (50% of face value), equal to INR 1.25 adjusted.
-
The FY25 and FY26 dividends were INR 1.50 on post-bonus shares (30% of face value).
-
There are no dilutive instruments, so basic and diluted EPS are identical.
Sources: StockAnalysis/S&P; board outcomes, May 2025 and May 2026.
Margins:
FY24–FY26 company EBITDA margins are as reported. FY22–FY23 are derived (company EBITDA divided by revenue from operations). Gross, EBIT and net margins are from S&P.
Growth:
-
Revenue CAGR FY22–FY26 (revenue from operations): 12.2% (derived: 771.7 / 486.6 over 4 years).
-
PAT CAGR FY22–FY26: 7.7% (derived).
-
EPS CAGR FY22–FY26: 7.7%.
-
Dividend-per-share CAGR FY22–FY26: 14.4% (derived).
Commentary. FY24 was the cyclical high. Revenue grew 22.7%, EBITDA margin reached 13.5%, and PAT rose 66% to INR 60.1 Cr. Two things drove it: the 1,800 MTPA capacity step-up and favourable realisations. Large mark-to-market and realised gains on mutual-fund investments also helped, at INR 10.7 Cr of investment gains (S&P).
FY25 was flat. Revenue grew 2.2%, while EBITDA margin fell to 10.6% and PAT fell 21% to INR 47.4 Cr. ICRA attributes this to price erosion in commoditised products, which offset volume growth.
FY26 brought the best volume growth in the period: production rose 25% to 1,733 MT and revenue grew 16.7%. Profit nonetheless fell again, by 13.3% to INR 41.0 Cr, for four reasons:
-
Gross margin compressed by about 230 bp, as cost of materials rose faster than revenue and trading mix increased (purchases of stock-in-trade doubled to INR 79.2 Cr).
-
Foreign-exchange losses rose to INR 6.1 Cr from INR 2.8 Cr (S&P).
-
Investment gains fell (INR 3.6 Cr vs INR 7.8 Cr).
-
Depreciation rose about 30% after the FY25 capex.
FY26 was therefore growth without operating leverage. The inflection appears to have come in H2 FY26 (Q3 EBITDA margin 10.6%) and was confirmed in Q1 FY27 (9.99% vs 7.34%).
Quarterly trajectory
Sources: FY25 audited results (Q3–Q4 FY25); Q3 FY26 results (Q2–Q3 FY26); Q1 FY27 results and presentation (Q4 FY26, Q1 FY26, Q1 FY27).
Notes:
-
The quarterly PATs for FY26 sum to INR 41.04 Cr, which reconciles to the audited annual figure.
-
Adjusted EBITDA, which excludes forex and mutual-fund mark-to-market, was 12.18% in Q3 FY26 and 9.26% for 9M FY26 (Q3 FY26 results, note 3).
-
Q4 FY26 EBITDA excluding other items was INR 23.56 Cr, down 18.3% YoY, on flat production of 426 MT (FY26 deck, Joint MD message).
Balance sheet
Sources: StockAnalysis/S&P balance sheet (updated 7 Aug 2026); FY25 audited statement of assets and liabilities (INR lakh).
Notes:
-
The FY25 short-term debt of INR 10.5 Cr was a stand-by letter of credit, not a term loan (ICRA, Sep 2025).
-
There is no goodwill.
-
Long-term debt other than leases is nil throughout.
-
The company's own balance sheet shows FY25 total investments (current and non-current) of INR 105.8 Cr, falling to INR 39.6 Cr non-current at FY26 (board outcome, May 2026). S&P classifies these differently, so cash figures vary by source.
Commentary. Equity grew at an 11.9% CAGR, entirely from retained earnings. The bonus capitalised INR 25.1 Cr of general reserve into share capital without changing net worth.
The critical change in FY26 was inventory, which doubled to INR 147.8 Cr from INR 74.5 Cr. Together with higher receivables, this lifted working capital by INR 50.6 Cr. It was funded by running down liquid investments, about INR 25 Cr net sold according to the S&P cash-flow line, and by stretching payables by INR 31 Cr. Whether the build is strategic stocking for regulated-market launches or a demand mismatch is the key unanswered question. Q1 FY27 shows a further inventory build of INR 15.8 Cr (change in inventories, Q1 FY27 results).
Cash flow
Sources: StockAnalysis/S&P cash-flow statement. The FY24 and FY25 operating cash flow and capex reconcile to the company's audited FY25 cash-flow statement (INR 1,292.52 lakh and INR 3,712.48 lakh operating cash flow; INR 1,996.29 lakh FY25 capex on PP&E).
Commentary. Cumulative FY22–FY26 FCF was about INR 94 Cr, against cumulative PAT of about INR 215 Cr. That is a FCF-to-PAT conversion of roughly 44%. Working-capital absorption explains the gap; capex does not, since cumulative capex was only about INR 36 Cr.
FY26 FCF was negative for the first time in the period. Dividends have been paid from balance-sheet liquidity rather than free cash flow in two of the last three years (FY24 and FY26).
Capex is unusually low for an API maker of this size, at about 1% of revenue in FY26. Capacity additions have been "brownfield debottlenecking": 40 KL of reactors added for the 2,200 to 2,400 MTPA step (FY26 directors' report).
Ratios
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Reported segment | Contents | Revenue FY26 (INR Cr) | Share of revenue | Segment PBT FY26 (INR Cr) |
|---|---|---|---|---|
Bulk drugs & chemicals | All APIs, intermediates and traded goods | 771.66 | 100% | 54.22 |
Revenue by Segment
| Product group (INR Cr) | FY2025 | FY2026 |
|---|---|---|
Erythromycin salts | 221 | 241 |
Higher macrolides (azithromycin) | 68 | 110 |
Sulphadoxine | 90 | 100 |
Corticosteroids | 102 | 82 |
Pyrazinamide | 38 | 42 |
Gliclazide | 28 | 21 |
Other items | 58 | 110 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Revenue (% of FY26 revenue from operations (771.66)–YoY growth FY26)
| Product group | YoY growth FY26 | % of FY26 revenue from operations (771.66) |
|---|---|---|
Erythromycin salts | +9.0% | 31.2% |
Higher macrolides | +61.8% | 14.3% |
Sulphadoxine | +11.1% | 13.0% |
Corticosteroids | -19.6% | 10.6% |
Pyrazinamide | +10.5% | 5.4% |
Gliclazide | -25.0% | 2.7% |
Other items | +89.7% | 14.3% |
Revenue by Segment (Quarterly)
| Product group (INR Cr) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Erythromycin | 63.6 | 49.1 |
Higher macrolides | 19.7 | 39.9 |
Sulphadoxine | 11.0 | 37.0 |
Corticosteroids | 20.9 | 20.1 |
Pyrazinamide | 10.3 | 12.2 |
Gliclazide | 5.1 | 11.9 |
Other items | 34.7 | 10.9 |
Ambroxol HCl | 8.4 | 7.9 |
Chloramphenicol | 12.2 | 4.0 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Revenue from operations (INR Cr) | 661.51 | 771.66 |
EBITDA incl. other income (INR Cr) | 70.36 | 66.08 |
EBITDA margin (%) | 10.64 | 8.56 |
PBT (INR Cr) | 61.01 | 54.22 |
PBT margin (%) | 9.22 | 7.03 |
Income Statement
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations | 486.6 | 527.5 | 647.0 | 661.5 | 771.7 |
Total revenue incl. other income (company) | 491.8 | 537.0 | 659.0 | 671.0 | 776.0 |
Gross profit (S&P) | 105.7 | 120.0 | 155.6 | 154.8 | 163.1 |
Operating income / EBIT (S&P) | 36.5 | 43.7 | 66.9 | 55.0 | 56.5 |
EBITDA (company basis, incl. other income) | 52.0 | 57.4 | 87.2 | 70.4 | 66.1 |
EBITDA (S&P basis) | 48.2 | 53.1 | 74.9 | 63.2 | 67.3 |
Depreciation & amortisation (S&P) | 11.9 | 9.6 | 8.5 | 8.6 | 11.3 |
Pre-tax income | 39.1 | 47.5 | 78.3 | 61.0 | 54.2 |
Income tax | 8.6 | 11.3 | 18.3 | 13.7 | 13.2 |
Net income (PAT) | 30.6 | 36.2 | 60.1 | 47.4 | 41.0 |
Per-Share Data
| Metric (INR per share) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS basic | 3.05 | 3.61 | 5.99 | 4.72 | 4.10 |
EPS diluted | 3.05 | 3.61 | 5.99 | 4.72 | 4.10 |
Dividend per share | 0.875 | 1.00 | 1.25 | 1.50 | 1.50 |
Margin (%)
| Margin (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 21.72 | 22.74 | 24.05 | 23.40 | 21.13 |
Operating (EBIT) margin | 7.51 | 8.29 | 10.34 | 8.31 | 7.32 |
EBITDA margin (company basis) | 10.69 | 10.88 | 13.48 | 10.64 | 8.56 |
Net margin | 6.28 | 6.86 | 9.28 | 7.16 | 5.32 |
Income Statement and Margin Analysis (%)
| Metric (INR Cr) | Q3FY2025 | Q4FY2025 | Q1FY2026 | Q2FY2026 | Q3FY2026 | Q4FY2026 | Q1FY2027 |
|---|---|---|---|---|---|---|---|
Revenue from operations | 159.5 | 198.1 | 186.5 | 185.9 | 197.2 | 202.1 | 193.8 |
EBITDA (company basis) | 15.7 | 20.1 | 13.7 | 12.9 | 20.9 | 18.6 | 19.4 |
EBITDA margin % | 9.86 | 10.13 | 7.34 | 6.92 | 10.60 | 9.22 | 9.99 |
PBT | 13.3 | 17.3 | 11.0 | 9.9 | 17.8 | 15.5 | 16.9 |
PAT | 10.3 | 12.5 | 8.3 | 7.6 | 13.5 | 11.7 | 11.4 |
EPS (INR, adjusted) | 1.03 | 1.25 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet and Per-Share Data
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 347.2 | 405.0 | 445.7 | 506.6 | 557.4 |
Cash & short-term investments | 25.3 | 53.1 | 62.3 | 73.4 | 52.9 |
Long-term investments | 21.2 | 39.7 | 51.7 | 62.0 | 39.6 |
Trade receivables | 135.7 | 171.2 | 189.9 | 215.9 | 238.6 |
Inventory | 79.9 | 72.6 | 75.4 | 74.5 | 147.8 |
Net PP&E | 61.3 | 52.7 | 49.2 | 58.4 | 56.1 |
Trade payables | 121.6 | 152.8 | 140.5 | 156.8 | 187.7 |
Short-term borrowings | 3.1 | 0.0 | 2.0 | 10.5 | 0.0 |
Lease liabilities (current + non-current) | 1.1 | 0.9 | 0.7 | 0.4 | 0.1 |
Total debt | 4.2 | 0.9 | 2.7 | 10.9 | 0.1 |
Net debt (negative = net cash; excl. LT investments) | -21.0 | -52.2 | -59.6 | -62.5 | -52.9 |
Shareholders' equity | 213.8 | 241.2 | 291.2 | 326.0 | 352.2 |
Goodwill & intangibles | 0.2 | 0.1 | 0.2 | 0.1 | 0.5 |
Working capital | 127.8 | 146.3 | 185.8 | 197.7 | 248.3 |
Book value per share (INR) | 21.33 | 24.07 | 29.06 | 32.53 | 35.14 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 28.9 | 53.9 | 12.9 | 37.1 | -3.0 |
Capital expenditure | 1.6 | 1.6 | 5.0 | 20.1 | 7.9 |
Free cash flow | 27.2 | 52.4 | 7.9 | 17.0 | -10.9 |
Dividends paid | 7.6 | 8.7 | 10.0 | 12.5 | 15.0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Change in working capital | -9.3 | 16.4 | -43.6 | -13.1 | -54.9 |
Cash taxes paid | 9.1 | 13.5 | 19.1 | 11.1 | 13.2 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE % (on average equity; FY22 on closing equity) | 14.3 | 15.9 | 22.6 | 15.3 | 12.1 |
ROA % (on average assets; FY22 on closing assets) | 8.8 | 9.6 | 14.1 | 9.9 | 7.7 |
ROCE % (Screener) | 18 | 19 | 26 | 17 | 16 |
Current ratio (x, company) | 1.98 | 1.91 | 2.20 | 2.11 | 2.22 |
Debt / equity (x, company) | 0.01 | 0.00 | 0.01 | 0.03 | 0.00 |
Net debt / EBITDA (x, company EBITDA; negative = net cash) | -0.40 | -0.91 | -0.68 | -0.89 | -0.80 |
Interest coverage (EBIT / interest, x, derived) | 38 | 200 | 189 | 89 | 120 |
Asset turnover (x) | 1.40 | 1.40 | 1.52 | 1.39 | 1.45 |
Cash conversion cycle (days, company) | 58 | 56 | 61 | 72 | 86 |
Revenue by Region
| Region (INR Cr) | FY2025 | FY2026 |
|---|---|---|
Domestic (India) | 297 | 417 |
Export | 365 | 355 |
Growth / share
| Growth / share | FY2026 |
|---|---|
Domestic growth YoY | +40.4% |
Export growth YoY | -2.7% |
Export share of revenue | 46% (company: "~46%") |
Revenue by Region (Quarterly)
| Region (INR Cr) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Domestic | 98 | 124 |
Export | 88 | 70 |
Revenue by Region (%)
| Region (% of exports) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Asia | 26.8 | 35.7 |
Europe | 35.5 | 29.6 |
Africa | 30.9 | 27.9 |
North America | 3.8 | 4.2 |
Latin America | 3.1 | 2.6 |
Revenue by Region (%) by Customer Concentration
| Customer concentration (%) | Q1FY2026 | Q1FY2027 |
|---|---|---|
Top 5 share of export sales | 37 | 30 |
Top 5 share of domestic sales | 55 | 34 |
Top 5 share of total sales | 36 | 20 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Last price | INR 83.05 (BSE close) | 16 Oct 2026, StockAnalysis/S&P |
52-week range | INR 66.72 – 99.50 | Anand Rathi (Sep 2026) |
52-week price change | +5.35% | S&P, 19 Oct 2026 |
50-day / 200-day moving average | INR 84.39 / INR 79.67 | S&P |
Beta (5Y) | 0.48 | S&P |
Average daily volume (20D) | About 13,400 shares | S&P |
Market cap / EV | INR 832 Cr / INR 779 Cr | S&P |
Return period
| Return period | Value (measured 22 Sep 2026, price INR 93.49) | Value (measured 28 Aug 2026, price INR 83.57) |
|---|---|---|
1-year | +8.9% | -4.5% |
3-year | +45.6% | +25.0% |
5-year | +58.4% | +39.1% |
Valuation Multiples
| Multiple | Anuh Pharma |
|---|---|
P/E (TTM EPS INR 4.40) | 18.85x |
EV/EBITDA (S&P EBITDA) | 10.47x |
EV/Sales | 1.00x |
P/B (BVPS INR 35.14) | 2.36x |
EV/EBIT | 12.46x |
Dividend yield | 1.81% |
Earnings yield / FCF yield | 5.31% / -1.31% |
Dividend (INR per share, adjusted)
| Dividend (INR per share, adjusted) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share | 0.875 | 1.00 | 1.25 | 1.50 | 1.50 |
Dividend outflow (INR Cr, company) | 8.77 | 10.02 | 12.53 | 15.03 | 15.03 |
Payout ratio % (Screener) | 29 | 28 | 21 | 16 | 37 |
Credit Ratings
| Agency | Instrument | Rating | Outlook | Date |
|---|---|---|---|---|
ICRA | Long-term fund-based (CC/WCDL, interchangeable; INR 5 Cr sub-limit) | [ICRA]A- | Positive | 15 Sep 2025 |
ICRA | Short-term (export credit, INR 60 Cr sub-limit; LC/SBLC/buyer's credit INR 90 Cr) | [ICRA]A2+ | — | 15 Sep 2025 |
ICRA | Long/short-term interchangeable (bank guarantee, INR 90 Cr sub-limit) | [ICRA]A- (Positive) / [ICRA]A2+ | Positive | 15 Sep 2025 |
Moody's / S&P / Fitch | — | Not rated | — | — |
Analyst Conclusions
Management guidance
Revenue: "steady" growth of 15–20% per annum, reiterated in the May 2026 and August 2026 decks. That implies FY27 revenue of roughly INR 887–926 Cr (derived).
Drivers cited: regulated-market expansion after the USFDA and EU GMP clearances, product-mix enrichment, cost control and better throughput.
No guidance: on margins, capex quantum or dividends.
Consensus
No sell-side consensus exists. The market-implied view is that a P/E of about 19x and EV/EBITDA of about 10.5x price in modest growth and a partial margin recovery.
Bull case
-
Margin mean-reversion is under way. EBITDA margin recovered from 6.92% (Q2 FY26) to 10.60% (Q3), 9.22% (Q4) and 9.99% (Q1 FY27). Q1 FY27 ROCE was 19.18%, against 15.92% for FY26. If FY27 EBITDA margins hold at about 10% on 15% growth, EBITDA would be about INR 89 Cr, a new high (derived).
-
Regulatory optionality is cheap. A zero-483 USFDA outcome (2026), new WHO-PQ (amodiaquine) and new CEPs give access to US, EU and institutional markets. North America is still only about 4% of exports, so even modest US wins would be material for a company valued at about INR 830 Cr.
-
The balance sheet funds growth and payouts. About INR 90 Cr of cash and investments, no debt, and capex of only INR 8–20 Cr a year mean the company can absorb working-capital build, sustain the INR 1.50 dividend, and pursue backward integration without dilution. ICRA's Positive outlook offers an upgrade path.
Bear case
-
Growth without profit has persisted. FY26 revenue rose 16.7% while PAT fell 13.3%. Cumulative FY22–FY26 FCF covered only about 44% of PAT. Q1 FY27 revenue grew just 3.9%, making the 15–20% target already stretched.
-
Working capital is consuming the business. The cash conversion cycle rose to 86 days and inventory doubled. If the inventory build reflects slow-moving stock rather than pre-launch stocking, write-downs or price-cutting would follow.
-
The commodity trap and concentration. About 31% of revenue comes from erythromycin, which fell 23% YoY in Q1 FY27. Exports appear to have declined YoY in Q1 FY27 (on the reconciling reading). All production is at one site. ICRA's 7% margin floor was breached in Q2 FY26, so another weak quarter could hit the rating outlook.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| About 13 Nov 2026 | Q2 FY27 results. Can margin stay near 10% while growth rebounds toward 15%+? |
| Q2–Q3 FY27 | Inventory and receivables trend; whether the cash conversion cycle reverts toward 60–70 days |
| Q3 FY27 | Export trajectory, Europe and North America in particular; first US commercial supplies after the USFDA inspection |
| Through FY27 | Regulatory filings and approvals for pipeline molecules (vonoprazan, edoxaban, pretomanid, bisoprolol, ticagrelor) |
| Through FY27 | WHO-linked tender wins in anti-malarials and anti-TB (sulfadoxine/amodiaquine, pyrazinamide/isoniazid) |
| Around Sep 2026 – early 2027 | ICRA surveillance: possible upgrade to A or reversion to Stable |
| FY27 | Capital allocation: use of surplus treasury (capex, backward integration, a second site) and the dividend decision (May 2027) |
| Ongoing | Promoter-group actions (reclassification, holding changes) and related-party transactions under the revised RPT policy |
Analyst verdict
Anuh Pharma is a well-run, conservatively financed, but structurally low-return API converter. It is trying to climb the value chain, and the evidence of the past three years points in two directions at once.
On the operating side, the company has done what a small API maker must do to earn the right to grow. It added capacity cheaply, from 1,800 to 2,400 MTPA, and lifted production by a quarter in FY26. It also widened its regulatory perimeter: a clean USFDA inspection, fresh CEPs and a new WHO pre-qualification. The Q1 FY27 numbers suggest mix is finally helping. Sulphadoxine, higher macrolides and gliclazide are replacing low-margin trading and weaker erythromycin, and EBITDA margin has recovered to about 10%.
On the financial side, three years of evidence point the other way. Gross margins remain in the low twenties, profits are below their FY24 peak, and working capital is absorbing most of the earnings. FY26 produced negative operating cash flow even as revenue reached a record. The 15–20% growth guidance looks ambitious against a Q1 that grew under 4%. The company also discloses too little on R&D, export customers and the inventory build for investors to judge whether the new pipeline will change the economics.
At about 19x trailing earnings and about 10.5x EV/EBITDA, the stock is not demanding for a net-cash company with ICRA A- (Positive) credit and a five-year dividend-growth record. Nor does it price much failure.
The investment case reduces to one testable proposition: can Anuh hold about 10% EBITDA margins while converting its regulatory credentials into above-15% growth and reversing the cash-conversion slippage? Q2 and Q3 FY27 results will largely answer it.
Until then, the balance of evidence supports a neutral-to-constructive stance. Downside is cushioned by the balance sheet and dividend. Upside depends on execution evidence that has only just begun to appear.
APPENDIX — SOURCES
-
Anuh Pharma, Investor Presentation Q1 FY2026-27 (NSE filing, 19 Aug 2026) — nsearchives.nseindia.com/corporate/ANUHNSE_19082026165402_Intimation_for_investor_presentation.pdf
-
Anuh Pharma, Unaudited Financial Results Q1 FY27 (NSE filing, 7 Aug 2026) — nsearchives.nseindia.com/corporate/ANUHNSE_07082026181608_Financials.pdf
-
Anuh Pharma, Outcome of Board Meeting and FY26 Audited Results (NSE filing, 20 May 2026) — nsearchives.nseindia.com/corporate/ANUHNSE_20052026230618_Outcome_of_Board_Meeting.pdf
-
Anuh Pharma, Unaudited Results Q3 FY26 (BSE filing, 6 Feb 2026) — bsmedia.business-standard.com (announcement bd82a7c8)
-
Anuh Pharma, Reg. 30 USFDA inspection disclosure (6 Feb 2026) — bsmedia.business-standard.com (announcement 1e41ffca)
-
Anuh Pharma, Outcome of Board Meeting and FY25 Audited Results (23 May 2025) — bsmedia.business-standard.com (announcement 1fe6019a)
-
Anuh Pharma, Investor Presentation Q2 FY2025-26 (NSE filing, 17 Nov 2025)
-
NSE Circular NSE/CML/69079 — Listing of bonus shares (11 Jul 2025)
-
Anuh Pharma, Withdrawal of NSE direct listing application (BSE filing, 10 Mar 2022)
-
ICRA, Anuh Pharma Limited: Ratings reaffirmed (15 Sep 2025) — icra.in rationale 137612
-
ICRA rationales: Jan 2025 (outlook to Positive), Dec 2023, Aug 2021, Oct 2020, Aug 2018
-
Multibagg AI, "Anuh Pharma FY2026: Strong growth, tighter margins" (30 May 2026)
-
StockAnalysis.com (S&P Global Market Intelligence data) — income statement, balance sheet, cash flow, statistics for BOM:506260 / NSE:ANUHPHR (accessed Oct 2026)
-
Screener.in — Anuh Pharma company pages (accessed 2025–2026)
-
Indian Pharma Post, "Anuh Pharma PAT grew 37.63% to Rs. 11.42 crore in Q1 FY27" (19 Aug 2026)
-
Sahi.com, Anuh Pharma Q1 FY27 and growth-guidance coverage (Aug 2026)
-
Quartr, Anuh Pharma Q1 FY26-27 earnings summary (Aug 2026)
-
IIFL / IndiaInfoline — Anuh Pharma directors' report FY26 and company summary (2026)
-
Pharma Now, "USFDA Completes Inspection of Anuh Pharma's Facilities Without Form 483 Observation" (9 Feb 2026)
-
Medical Dialogues / DSIJ — 2019 USFDA inspection coverage (Sep 2019)
-
Anand Rathi, Upstox, Kotak Neo, Finology, IndMoney, Research360, MarketsMojo — share price and return data (2025–2026)
-
Ipca Laboratories, NSE filing on Tarapur USFDA inspection (5 Dec 2025) — industry context
-
Aarti Drugs FY26 results — Indian Pharma Post (19 May 2026); FilingReader (16 May 2026); Quartr AGM 2026 summary; Anand Rathi financials
-
Supriya Lifescience FY26 results — Indian Pharma Post; Arihant Capital (May 2026)
-
Aarti Pharmalabs FY26 results — Trendlyne summary (May 2026)
-
Anuh Pharma 56th Annual Report FY2015-16 (BSE) — historical context
-
RegisterKaro / MCA-derived company data — incorporation details
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / appointment | Background | Age | Source |
|---|---|---|---|---|---|
Arun Todarwal | Chairman | Not disclosed. Named among directors retiring by rotation at the 66th AGM (FY26 directors' report), which implies non-independent status; independence classification not confirmed. | Fellow of ICAI, in practice since 1981. Director of several large listed companies, serving on audit, risk, nomination-and-remuneration and ESG/CSR committees. | — | Q1 FY27 presentation; FY26 directors' report |
Bipin N. Shah | Vice Chairman (Promoter) | With Anuh since inception as MD | Bachelor's in Chemical Engineering; President of the Thane Belapur Industries Association | — | Q1 FY27 presentation |
Ritesh B. Shah | Joint Managing Director (Promoter) | Reappointed for 5 years from 8 Jan 2026 to 7 Jan 2031 | BSc Chemistry, MBA. Led international marketing for over 20 years; marketing, finance, strategy and sourcing. Son of Bipin Shah. | 44 (May 2025) | Board outcome, May 2025 |
Vivek B. Shah | Joint Managing Director (Promoter) | Reappointed for 5 years from 8 Jan 2026 to 7 Jan 2031 | MSc Biotechnology. Has led manufacturing and R&D since 2009; operations, R&D and regulatory affairs. Son of Bipin Shah. | — | Board outcome, May 2025 |
Bharat N. Shah | Non-executive, non-independent director | Reappointed on rotation, 22 Aug 2025 | About five decades in pharma across SK Group formulations, APIs, exports and R&D. Brother of Bipin Shah. | — | Board outcome, May 2025 |
Gaurav S. Shah | Non-executive, non-independent director | Reappointed on rotation, 22 Aug 2025 | BE (Computers, USA); NMIMS diploma in family-managed business; 20 years in formulations, APIs and logistics. Nephew of Bipin Shah. | — | Board outcome, May 2025 |
Independent directors | — | Names and number not identified in sources reviewed | — | — | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Background |
|---|---|---|
Raju Kotadia | Chief Marketing Officer — Emerging Markets | BSc Chemistry; with Anuh since inception; overall sales management |
Vinayak Shenoy | Chief Marketing Officer — "MM" (regulated markets inferred) | MBA Marketing; 15+ years in APIs and intermediates across the USA, Europe, CIS, SE Asia, LatAm and India |
Sanjay Barhate | VP Quality | MSc, MPhil Chemistry; 34 years in plant and corporate quality |
Darshan Rampariya | Chief Financial Officer (and investor contact) | Chartered Accountant; 17+ years in audit, tax, finance and investor relations |
Manan Vadhan | Company Secretary & Compliance Officer | ACS; 4+ years in secretarial compliance |
Dr. Sanjay Vaidya | GM R&D | 25 years in industrial process research on API molecules |
Gulshan Sharma | GM Works | BTech (Chemical & Pharmaceutical); 21+ years in API and food industries |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
23 May 2025 | Joint MDs Ritesh and Vivek Shah reappointed (effective 8 Jan 2026) | Continuity of second-generation family leadership |
22 Aug 2025 | Bharat N. Shah and Gaurav S. Shah reappointed on rotation | Routine |
Q2 FY26 (Jul–Sep 2025) | A "leadership addition" is noted in an aggregator summary of the Q2 FY26 filing; the role appears to be a senior marketing hire | Unconfirmed. Vinayak Shenoy (CMO-MM) appears in later decks. |
Aug 2026 | Arun Todarwal, among others, retires by rotation and is eligible for reappointment at the 66th AGM | Routine |
Major Shareholders
| Holder category | Stake | Date | Source |
|---|---|---|---|
Promoter & promoter group | 71.80% | 10 Aug 2026 | Q1 FY27 presentation |
Public (non-promoter) | 28.20% | 10 Aug 2026 | Q1 FY27 presentation |
Institutions (FII + DII) | About 0% | Jun 2026 | StockAnalysis/S&P; Craytheon (DII 0.0%) |
Insiders (S&P definition) | 72.67% | Oct 2026 | StockAnalysis/S&P |
Promoter pledge | Zero | May 2026 | Research360 |
Competitive Landscape
Competitor Detail
| Franchise | Named competitors (India / global) | Notes |
|---|---|---|
Erythromycin salts and macrolides | Chinese fermentation-integrated erythromycin and macrolide producers (the dominant source of erythromycin thiocyanate); Indian macrolide API makers such as Alembic Pharmaceuticals, Aurobindo Pharma and Hetero (azithromycin/clarithromycin) | Anuh claims India #1 and global top-5 in erythromycin salts (ICRA). It depends on fermentation-based upstream supply. |
Corticosteroids | Symbiotec Pharmalab (India, private); Chinese steroid API producers; European steroid specialists | Price-competitive; Anuh's steroid revenue fell 20% in FY26 |
Anti-TB (pyrazinamide, isoniazid, ethambutol) | Lupin (historically a major anti-TB API maker); Chinese producers; Macleods (formulations-focused) | Anuh claims the world's largest pyrazinamide production |
Anti-malarials (sulfadoxine, pyrimethamine, amodiaquine) | Ipca Laboratories (major anti-malarial API producer); Mangalam Drugs & Organics; Chinese producers | WHO-PQ is an entry barrier |
Anti-diabetics (gliclazide, DPP-4, SGLT2) | Aarti Drugs; many Indian API makers entering gliptins and gliflozins | Crowded generic space |
Chloramphenicol / sulfonamides | Chinese producers; smaller Indian producers | Commodity |
Diversified mid-cap API peers (benchmarks) | Aarti Drugs, Supriya Lifescience, Aarti Pharmalabs, IOL Chemicals & Pharmaceuticals, Solara Active Pharma Sciences, Shilpa Medicare | Capital-markets peer set |
Peer Comparison FY2026
| Metric | Anuh Pharma | Aarti Drugs | Supriya Lifescience | Aarti Pharmalabs |
|---|---|---|---|---|
FY26 revenue (INR Cr) | 771.7 | 2,567.7 (consolidated) | 827.9 (consolidated) | 1,819.4 (consolidated) |
Revenue growth YoY | +16.7% | +7% | +18.9% | -14.0% |
EBITDA margin | 8.6% (company basis) | 12.1% | 35.5% | — |
PAT (INR Cr) | 41.0 | 194.9 | 209.1 | 174.7 (consolidated) |
PAT margin | 5.3% | 7.6% | 25.3% | about 9.6% (derived) |
Export share of revenue | about 46% | about 38% | about 82% | — |
ROCE | 15.9% (FY26) | 11.5% (FY26) | — | — |



